ACAD
37.04
+0.3
+0.82%
AEMD
6.23
-0.06
-0.95%
APRI
0.309
-0.012
-3.8641%
ARNA
1.67
-0.01
-0.60%
ATEC
0.41
+0.03
+7.92%
CNAT
2.26
-0.03
-1.31%
CRXM
0.177
-0.003
-1.667%
CYTX
2.17
+0.12
+5.85%
DXCM
92.23
+2.67
+2.98%
GNMK
10.65
+0.39
+3.80%
HALO
9.94
+0.17
+1.74%
ILMN
166.35
-0.07
-0.04%
INNV
0.54
-0.01
-1.80%
INO
9.88
+0.26
+2.70%
ISCO
1.99
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
134.88
-0.01
-0.01%
LPTN
1.95
-0.05
-2.50%
MBVX
0.6
-0.05
-7.69%
MEIP
1.36
0.00
-0.01%
MNOV
6.2
+0.13
+2.14%
MRTX
4.64
+0.08
+1.75%
MSTX
0.357
-0.006
-1.6249%
NBIX
50.23
+0.08
+0.16%
NUVA
62.2
+0.18
+0.29%
ONCS
1.82
+0.03
+1.68%
ONVO
4.28
-0.01
-0.23%
OREX
3.35
-0.03
-0.89%
OTIC
14.36
-0.1
-0.69%
QDEL
22.8
-0.44
-1.89%
RCPT
231.96
0.00
0.00%
RGLS
3.57
0.00
+0.14%
RMD
68.88
+3.18
+4.84%
SPHS
5.86
+0.46
+8.52%
SRNE
6.29
+0.1
+1.62%
TROV
5.63
+0.18
+3.30%
VICL
4.15
-0.05
-1.19%
VOLC
18
0.00
0.00%
ZGNX
9.13
+0.05
+0.55%
ACAD
37.04
+0.3
+0.82%
AEMD
6.23
-0.06
-0.95%
APRI
0.309
-0.012
-3.8641%
ARNA
1.67
-0.01
-0.60%
ATEC
0.41
+0.03
+7.92%
CNAT
2.26
-0.03
-1.31%
CRXM
0.177
-0.003
-1.667%
CYTX
2.17
+0.12
+5.85%
DXCM
92.23
+2.67
+2.98%
GNMK
10.65
+0.39
+3.80%
HALO
9.94
+0.17
+1.74%
ILMN
166.35
-0.07
-0.04%
INNV
0.54
-0.01
-1.80%
INO
9.88
+0.26
+2.70%
ISCO
1.99
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
134.88
-0.01
-0.01%
LPTN
1.95
-0.05
-2.50%
MBVX
0.6
-0.05
-7.69%
MEIP
1.36
0.00
-0.01%
MNOV
6.2
+0.13
+2.14%
MRTX
4.64
+0.08
+1.75%
MSTX
0.357
-0.006
-1.6249%
NBIX
50.23
+0.08
+0.16%
NUVA
62.2
+0.18
+0.29%
ONCS
1.82
+0.03
+1.68%
ONVO
4.28
-0.01
-0.23%
OREX
3.35
-0.03
-0.89%
OTIC
14.36
-0.1
-0.69%
QDEL
22.8
-0.44
-1.89%
RCPT
231.96
0.00
0.00%
RGLS
3.57
0.00
+0.14%
RMD
68.88
+3.18
+4.84%
SPHS
5.86
+0.46
+8.52%
SRNE
6.29
+0.1
+1.62%
TROV
5.63
+0.18
+3.30%
VICL
4.15
-0.05
-1.19%
VOLC
18
0.00
0.00%
ZGNX
9.13
+0.05
+0.55%
Home » Archive by Category

Xconomy

Two Years After Paying $680M, BioMarin Shelves Duchenne Drug

May 31, 2016 – 2:44 pm

BioMarin Pharmaceutical took a $680 million gamble when it bought Prosensa in 2014 for its experimental Duchenne muscular dystrophy treatment. Drisapersen (Kydrisa) had already failed a Phase 3…

[[Click headline to continue reading.]]

With Recruits Coming, Precision Med Effort Pledges $142M For Biobank

May 27, 2016 – 11:56 am

The Obama administration’s ambitious long-term health study, dubbed the Precision Medicine Initiative, has tapped the Mayo Clinic to build a repository for biological samples collected from the…

[[Click headline to continue reading.]]

Biotech Roundup: Duchenne Delay, Forum’s Fate, Califf, Ionis & More

May 27, 2016 – 5:40 am

Memorial Day weekend may be fast approaching, but don’t fire up those grills yet: there’s plenty of headlines to dig into first in our biotech trip around the Xconomy network. In New York, the…

[[Click headline to continue reading.]]

FDA Commish Califf to Big Data Crowd: Flood Of New Treatments Coming

May 26, 2016 – 1:31 pm

New FDA commissioner Robert Califf said Wednesday that the recent spike in drug approvals is no temporary phenomenon, thanks to a better understanding of biology and continued adoption of…

[[Click headline to continue reading.]]

Sophiris Streamlines Operations, Weighs Options on Prostate Drug

May 24, 2016 – 11:53 pm

[Updated 5/25/16 2:35 pm with analyst comments. See below.] After advancing its experimental prostate drug to late-stage clinical trials, San Diego-based Sophiris Bio (NASDAQ: SPHS) has been…

[[Click headline to continue reading.]]

The Biotech Roundup: Immunotherapy Ups And Downs, Gene Deals & More

May 20, 2016 – 3:30 am

A quick housekeeping note: Starting this week, we are combining our East Coast and West Coast biotech roundups into a single weekly post that will also include highlights from our other cities and…

[[Click headline to continue reading.]]

Biogen Turns To UPenn Gene Therapy Pioneers in Wide-Ranging Alliance

May 16, 2016 – 3:55 am

Even though it recently decided to unload a gene therapy for hemophilia into a yet-to-be-named spin-out company, Biogen, one of biotech’s most risk-taking firms, is doubling down on gene…

[[Click headline to continue reading.]]

White House Wants to Spend $121M on National Microbiome Initiative

May 13, 2016 – 12:35 pm

The Obama administration announced this morning a public-private initiative to study the collections of microorganisms that live on or in humans and practically everywhere else on Earth. More than…

[[Click headline to continue reading.]]

MGH Goes Epic: What I Learned in the Trenches

May 10, 2016 – 5:45 am

On April 2 at Massachusetts General Hospital (MGH), the green charts went away. Every morning around 6:30 am since starting residency, my co-interns and I had frantically scrambled around the halls…

[[Click headline to continue reading.]]

Across The Board: Ideas To Narrow Biotech’s Gender Gap

May 10, 2016 – 3:30 am

The evidence is piling up. Companies with more women in charge are better businesses. So why are so many biotechs still led mainly by men? Saira Ramasastry, a former Merrill Lynch analyst, is now a…

[[Click headline to continue reading.]]